Get the Stockscreener App
45.41
6.08%
-2.94
Edgewise Therapeutics Inc stock is traded at $45.41, with a volume of 1.07M.
It is down -6.08% in the last 24 hours and up +37.94% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$48.35
Open:
$48.09
24h Volume:
1.07M
Relative Volume:
0.76
Market Cap:
$4.89B
Revenue:
-
Net Income/Loss:
$-176.01M
P/E Ratio:
-27.34
EPS:
-1.661
Net Cash Flow:
$-148.97M
1W Performance:
+14.79%
1M Performance:
+37.94%
6M Performance:
+82.37%
1Y Performance:
+227.40%
1-Day Range:
$43.81
$48.13
1-Week Range:
$39.27
$48.40
52-Week Range:
$12.30
$48.40
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
45.41 | 4.89B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Is Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Year - Kavout | AI
Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain - Trefis
Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51 - Moomoo
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Oppenheimer Initiates Edgewise Therapeutics at Outperform - Moomoo
EWTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says - Moomoo
Oppenheimer initiates Edgewise Therapeutics stock with outperform rating - Investing.com
Price to book forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics stock hits all-time high at 43.96 USD - Investing.com UK
Edgewise Therapeutics stock hits all-time high at 43.96 USD By Investing.com - Investing.com South Africa
Price to earnings forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - AOL.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
(EWTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Guggenheim Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51 - Moomoo
Guggenheim raises Edgewise Therapeutics stock price target on Servier deal By Investing.com - Investing.com Canada
EWTXEdgewise Therapeutics Inc Options - Finviz
Edgewise Therapeutics(EWTX.US) Officer Sells US$7.88 Million in Common Stock - Moomoo
Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m By Investing.com - Investing.com South Africa
Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m - Investing.com
Form 4 Edgewise Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares - Stock Titan
Form 4 Edgewise Therapeutics Inc For: 1 July By Investing.com - Investing.com India
Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant - Stock Titan
[144] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan
Form 144 | Edgewise Therapeutics(EWTX.US) Director Proposes to Sell 8.13 Million in Common Stocks - Moomoo
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Edgewise lures 2 new employees with 16,500 stock options - Stock Titan
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? - Insider Monkey
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Stocktwits
EWTX News | EDGEWISE THERAPEUTICS INC (NASDAQ:EWTX) - ChartMill
Edgewise Therapeutics, Inc. Actuals & Estimates (NASDAQ:EWTX) - TradingView
(EWTX) Risk Channels and Responsive Allocation - Stock Traders Daily
EWTX Forecast — Price Target — Prediction for 2027 - TradingView
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data - Yahoo Finance
Edgewise Therapeutics stock surges 8.94% to $42.30 as company gears up for EAN poster reveal - Traders Union
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release - Sahm
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
Edgewise Therapeutics stock hits all-time high at 40.87 USD - Investing.com
Edgewise Therapeutics stock hits all-time high at 40.87 USD By Investing.com - Investing.com Australia
Edgewise Therapeutics stock jumps 5.89 percent as company readies for BIO 2026 event - Traders Union
RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk - Moomoo
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - Moomoo
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Institutional Confidence - TradingKey
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):